Orchestra BioMed (NASDAQ:OBIO) Stock: Insider David Hochman Acquires 5,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman acquired 5,000 shares of the company’s stock in a transaction on Monday, November 9th. The shares were bought at an average cost of $5.00 per share, with a total value of $25,000.00. Following the acquisition, the insider directly owned 437,916 shares in the company, valued at approximately $2,189,580. The trade was a 1.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Orchestra BioMed Price Performance

Shares of OBIO stock opened at $5.73 on Wednesday. The company has a quick ratio of 8.24, a current ratio of 8.26 and a debt-to-equity ratio of 1.80. Orchestra BioMed Holdings, Inc. has a 12-month low of $3.46 and a 12-month high of $6.50. The stock’s 50-day moving average price is $5.77 and its 200-day moving average price is $4.59.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.10. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.13 million. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. Analysts expect that Orchestra BioMed Holdings, Inc. will post -1.53 earnings per share for the current year.

Orchestra BioMed News Roundup

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: The company said its BACKBEAT Global Pivotal Trial of AVIM Therapy completed enrollment with 349 patients, exceeding its target. It plans to submit primary-endpoint data for a late-breaking presentation at Heart Rhythm Society 2027, giving investors a future clinical milestone to watch. Company third-quarter results and business updates
• Positive Sentiment: Several executives and directors bought shares at $5 each on November 9. Purchases included 20,000 shares each by directors David Pacitti and Eric Fain, 5,000 by David Hochman, and 1,000 by CFO Andrew Taylor. Insider buying can signal confidence, though it does not guarantee future performance. Insider purchase report
• Neutral Sentiment: OBIO reported a third-quarter loss of $0.30 per share, narrower than analysts’ expected $0.40 loss and the $0.40 loss a year earlier. However, revenue of $0.09 million missed the $0.13 million consensus estimate, tempering the earnings beat. Q3 earnings report

Hedge Funds Weigh In On Orchestra BioMed

A number of large investors have recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC purchased a new stake in shares of Orchestra BioMed during the 1st quarter valued at $81,000. Canada Pension Plan Investment Board acquired a new position in Orchestra BioMed during the 2nd quarter valued at about $91,000. Bank of America Corp DE purchased a new stake in shares of Orchestra BioMed during the second quarter worth about $103,000. AXQ Capital LP purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at approximately $110,000. Finally, Algert Global LLC grew its position in Orchestra BioMed by 94.4% during the 2nd quarter. Algert Global LLC now owns 28,486 shares of the company’s stock worth $123,000 after purchasing an additional 13,830 shares during the last quarter. 53.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on OBIO shares. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Friday, October 23rd. Piper Sandler reaffirmed an “overweight” rating on shares of Orchestra BioMed in a research note on Thursday, October 15th. B. Riley Financial raised their price target on Orchestra BioMed from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a report on Monday, October 5th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.17.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization. Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.